Combination of Veliparib + Lapatinib for Breast Cancer

Phase-Based Progress Estimates
University of Alabama at Birmingham, Birmingham, ALBreast CancerCombination of Veliparib + Lapatinib - Drug
What conditions do you have?

Study Summary

This trial will study the effectiveness of two drugs, Veliparib and Lapatinib, for treating metastatic triple negative breast cancer.

Eligible Conditions
  • Metastatic Breast Cancer, Triple Negative Breast Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: baseline to 4 years

4 years post baseline
Number of subjects with objective response rate (ORR) at 4 years post baseline (Complete responses [CRs] plus partial responses [PRs]
Baseline to 4 years
Number of subjects with progression free survival (PFS) at 4 years after start of study.
Day 28
Therapeutic procedure
Day 10
Peak Plasma concentration of Veliparib and Palatinib when given in combination.
Week 4
Therapeutic procedure
baseline to 4 years
Number of subjects experiencing study-related toxicities when taking Veliparib in Combination with Lapatinib
baseline to cycle 1
Therapeutic procedure

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Combination of Veliparib + Lapatinib
1 of 1

Experimental Treatment

23 Total Participants · 1 Treatment Group

Primary Treatment: Combination of Veliparib + Lapatinib · No Placebo Group · N/A

Combination of Veliparib + Lapatinib
Experimental Group · 1 Intervention: Combination of Veliparib + Lapatinib · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 4 years

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,452 Previous Clinical Trials
2,244,014 Total Patients Enrolled
27 Trials studying Breast Cancer
4,296 Patients Enrolled for Breast Cancer
Breast Cancer Research Foundation of AlabamaUNKNOWN
1 Previous Clinical Trials
40 Total Patients Enrolled
AbbVieIndustry Sponsor
853 Previous Clinical Trials
473,928 Total Patients Enrolled
7 Trials studying Breast Cancer
454 Patients Enrolled for Breast Cancer
GlaxoSmithKlineIndustry Sponsor
4,663 Previous Clinical Trials
7,950,389 Total Patients Enrolled
32 Trials studying Breast Cancer
2,326,144 Patients Enrolled for Breast Cancer
Andres Forero, MDPrincipal InvestigatorUniversity of Alabama at Birmingham
2 Previous Clinical Trials
50 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 22 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You may be given bisphosphonates, but any changes in bone lesions cannot be used to measure your progress or response to the treatment.
You are expected to live for at least 12 more weeks.

Frequently Asked Questions

How many participants will be accepted in this clinical exploration?

"Unfortunately, recruitment for this research has already concluded. It was initially posted on September 1st 2014 and last reviewed on February 25th 2022. However, 2354 medical trials are presently recruiting participants with breast cancer while 42 studies related to the combination of Veliparib + Lapatinib currently require patients." - Anonymous Online Contributor

Unverified Answer

What maladies can be alleviated with the Veliparib + Lapatinib combination therapy?

"Combination of Veliparib + Lapatinib is a viable solution for postmenopausal women, breast cancer patients and those seeking advance directives." - Anonymous Online Contributor

Unverified Answer

Are there any preceding research examining the effects of Veliparib and Lapatinib administered together?

"Currently, 11 Combination of Veliparib + Lapatinib clinical trials are in Phase 3 with 42 ongoing studies. Though Lexington is the epicentre for these investigations, there exist 4371 sites globally conducting related research." - Anonymous Online Contributor

Unverified Answer

Are investigators currently adding participants to this research endeavor?

"This medical trial is no longer accepting new patients. Initially posted on September 1st, 2014 and last updated February 25th 2022, participants should look elsewhere for clinical trials. At present, 2354 studies are recruiting individuals with a diagnosis of breast cancer while 42 separate investigations need volunteers to combine veliparib + lapatinib medications." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.